Jeito Capital, a global private equity firm focused on biopharma, announced the final close of its second fund, Jeito II Fund, at $1.2 billion, exceeding its €1 billion target and marking the largest raise ever achieved by a fully independent European fund dedicated to biopharma.
With this milestone, Jeito Capital has tripled its assets under management to €1.6 billion in just five years, following the €534 million close of its first fund in 2021. The new fund reinforces the firm’s position among leading global biopharma investors and signals strong investor confidence in its patient-driven investment strategy.
Jeito II will continue the firm’s established approach of investing in 15 to 20 high-potential clinical-stage biopharma companies, primarily in Europe, that are developing breakthrough therapies targeting severe diseases and unmet medical needs. The…
